SG11201912168TA - Novel substituted xanthine derivatives - Google Patents
Novel substituted xanthine derivativesInfo
- Publication number
- SG11201912168TA SG11201912168TA SG11201912168TA SG11201912168TA SG11201912168TA SG 11201912168T A SG11201912168T A SG 11201912168TA SG 11201912168T A SG11201912168T A SG 11201912168TA SG 11201912168T A SG11201912168T A SG 11201912168TA SG 11201912168T A SG11201912168T A SG 11201912168TA
- Authority
- SG
- Singapore
- Prior art keywords
- novel substituted
- xanthine derivatives
- substituted xanthine
- derivatives
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17180721 | 2017-07-11 | ||
PCT/EP2018/068366 WO2019011802A1 (en) | 2017-07-11 | 2018-07-06 | NEW SUBSTITUTED XANTHINE DERIVATIVES |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201912168TA true SG11201912168TA (en) | 2020-01-30 |
Family
ID=59325162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201912168TA SG11201912168TA (en) | 2017-07-11 | 2018-07-06 | Novel substituted xanthine derivatives |
Country Status (30)
Country | Link |
---|---|
US (1) | US10329292B2 (zh) |
EP (1) | EP3652176B1 (zh) |
JP (1) | JP7114702B2 (zh) |
KR (1) | KR20200030048A (zh) |
CN (1) | CN110997675B (zh) |
AR (1) | AR112448A1 (zh) |
AU (1) | AU2018299824B2 (zh) |
BR (1) | BR112019025611A2 (zh) |
CA (1) | CA3066922A1 (zh) |
CL (1) | CL2020000056A1 (zh) |
CO (1) | CO2019015102A2 (zh) |
CY (1) | CY1125014T1 (zh) |
DK (1) | DK3652176T3 (zh) |
EA (1) | EA039526B1 (zh) |
ES (1) | ES2903268T3 (zh) |
HR (1) | HRP20220029T1 (zh) |
HU (1) | HUE057600T2 (zh) |
IL (1) | IL271799B (zh) |
LT (1) | LT3652176T (zh) |
MX (1) | MX2020000402A (zh) |
PH (1) | PH12020500079A1 (zh) |
PL (1) | PL3652176T3 (zh) |
PT (1) | PT3652176T (zh) |
RS (1) | RS62826B1 (zh) |
SA (1) | SA519410851B1 (zh) |
SG (1) | SG11201912168TA (zh) |
SI (1) | SI3652176T1 (zh) |
TW (1) | TWI801398B (zh) |
UA (1) | UA124793C2 (zh) |
WO (1) | WO2019011802A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3894409B1 (en) * | 2018-12-12 | 2023-08-23 | Boehringer Ingelheim International GmbH | Substituted xanthine derivatives |
ES2964630T3 (es) * | 2018-12-12 | 2024-04-08 | Boehringer Ingelheim Int | Derivados de xantina sustituidos |
KR20220079907A (ko) * | 2019-10-04 | 2022-06-14 | 골드핀치 바이오 인코포레이티드 | 국소분절사구체경화증 및 당뇨병성 신장 질환의 바이오마커 기반 치료 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA007485B1 (ru) * | 2001-02-24 | 2006-10-27 | Берингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Производные ксантина, способ их получения, фармацевтическая композиция на их основе и способ ее получения |
US6869947B2 (en) * | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
EP2044029B1 (en) * | 2006-07-14 | 2011-01-26 | Pfizer Products Inc. | Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine |
RS56066B2 (sr) * | 2013-03-15 | 2018-09-28 | Hydra Biosciences Inc | Supstituisani ksantini i postupci za njihovu upotrebu |
TWI676626B (zh) * | 2014-04-23 | 2019-11-11 | 美商美國禮來大藥廠 | 抑制瞬時受體電位a1離子通道 |
WO2016023830A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
EP3180342B1 (en) * | 2014-08-11 | 2019-06-26 | Hydra Biosciences, Inc. | Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives |
EP3194367B1 (en) | 2014-09-17 | 2021-08-18 | Boehringer Ingelheim International GmbH | Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes |
-
2018
- 2018-07-06 WO PCT/EP2018/068366 patent/WO2019011802A1/en unknown
- 2018-07-06 SI SI201830519T patent/SI3652176T1/sl unknown
- 2018-07-06 SG SG11201912168TA patent/SG11201912168TA/en unknown
- 2018-07-06 JP JP2020523041A patent/JP7114702B2/ja active Active
- 2018-07-06 LT LTEPPCT/EP2018/068366T patent/LT3652176T/lt unknown
- 2018-07-06 PL PL18735588T patent/PL3652176T3/pl unknown
- 2018-07-06 AU AU2018299824A patent/AU2018299824B2/en active Active
- 2018-07-06 RS RS20211577A patent/RS62826B1/sr unknown
- 2018-07-06 BR BR112019025611-3A patent/BR112019025611A2/pt unknown
- 2018-07-06 ES ES18735588T patent/ES2903268T3/es active Active
- 2018-07-06 IL IL271799A patent/IL271799B/en unknown
- 2018-07-06 PT PT187355888T patent/PT3652176T/pt unknown
- 2018-07-06 EP EP18735588.8A patent/EP3652176B1/en active Active
- 2018-07-06 CA CA3066922A patent/CA3066922A1/en active Pending
- 2018-07-06 HR HRP20220029TT patent/HRP20220029T1/hr unknown
- 2018-07-06 KR KR1020207000260A patent/KR20200030048A/ko not_active Application Discontinuation
- 2018-07-06 DK DK18735588.8T patent/DK3652176T3/da active
- 2018-07-06 MX MX2020000402A patent/MX2020000402A/es unknown
- 2018-07-06 EA EA202090270A patent/EA039526B1/ru unknown
- 2018-07-06 HU HUE18735588A patent/HUE057600T2/hu unknown
- 2018-07-06 CN CN201880045961.0A patent/CN110997675B/zh active Active
- 2018-07-06 UA UAA202000735A patent/UA124793C2/uk unknown
- 2018-07-10 US US16/031,399 patent/US10329292B2/en active Active
- 2018-07-10 TW TW107123858A patent/TWI801398B/zh active
- 2018-07-11 AR ARP180101931 patent/AR112448A1/es unknown
-
2019
- 2019-12-18 SA SA519410851A patent/SA519410851B1/ar unknown
- 2019-12-30 CO CONC2019/0015102A patent/CO2019015102A2/es unknown
-
2020
- 2020-01-08 CL CL2020000056A patent/CL2020000056A1/es unknown
- 2020-01-10 PH PH12020500079A patent/PH12020500079A1/en unknown
-
2022
- 2022-01-12 CY CY20221100028T patent/CY1125014T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1255045A1 (zh) | 取代的氧代吡啶衍生物 | |
IL271607A (en) | New azaquinoline histories | |
IL283990A (en) | Modified oxopyridine derivatives | |
HK1252275A1 (zh) | 羥烷基噻二唑衍生物 | |
IL279938A (en) | History of spirochroman | |
IL271799A (en) | New transmuted xanthine histories | |
PL3359543T3 (pl) | Pochodne kukurbiturylu | |
PL3796975T3 (pl) | Pochodne sulfonyloaminobenzamidu | |
IL271290A (en) | Dihydro-pyrrolo-pyridine derivatives | |
IL283768A (en) | Xanthine histories are transmuted | |
PL3770162T3 (pl) | Pochodne dihydrochromenu | |
IL265182A (en) | proinsulin derivatives | |
HK1245796A1 (zh) | 黃嘌呤衍生物 | |
GB201806948D0 (en) | Derivatives | |
PT3319956T (pt) | Derivados de oxopiridina substituída |